Aktie NLBS NUTRALIFE BIOSCIENCES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen NutraLife BioSciences, Inc.

Aktien

NLBS

US67098B1070

NLBS

Markt geschlossen - OTC Markets
Andere Börsenplätze
 20:02:07 27.06.2024 		% 5 Tage % 1. Jan.
0,000001 USD -99,00 % Intraday Chart für NutraLife BioSciences, Inc. -.--% -99,50 %
2022 NutraLife BioSciences, Inc. berichtet über die Ergebnisse des dritten Quartals und der ersten neun Monate bis zum 30. September 2022 CI
2022 NutraLife Biosciences, Inc. schließt Master Distribution Agreement mit Whole Foods Full Spectrum Processing ab CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
NutraLife Biosciences (OTC: NLBS) Releases Q4 2022 Shareholder Update and Announces the Acquisition of Healthcare Concierges USA
NUTRALIFE BIOSCIENCES, INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
NutraLife BioSciences, Inc. (OTCPK : NLBS) entered into a Stock Exchange Agreement to acquire Healthcare Concierges USA, Inc. from Mrugesh Patel, Pinal Kerai and Aysha Khan for 2 million.
NUTRALIFE BIOSCIENCES, INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
NutraLife BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
NutraLife Biosciences (OTC: NLBS) Releases Q4 2022 Shareholder Update
NutraLife Biosciences Launches a Clinically Tested Focus Stimulant Under a Master Distribution Agreement
NutraLife Biosciences, Inc. Executes Master Distribution Agreement with Whole Foods Full Spectrum Processing
NUTRALIFE BIOSCIENCES, INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
NutraLife BioSciences, Inc. announced that it has received $0.04 million in funding
NUTRALIFE BIOSCIENCES, INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
NutraLife BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
NUTRALIFE BIOSCIENCES, INC : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)
Nutralife Biosciences Executes a Joint Venture Agreement With Emergent Health Corporation for the Co-Production, Co-Marketing, and Distribution of Emergent’s Line of Regenerative, and Other Health-Related Nutraceutical, Skincare and Pet Pro
Nutralife Biosciences Executes a Joint Venture Agreement With Emergent Health Corporation for the Co-Production, Co-Marketing, and Distribution of Emergent’s Line of Regenerative, and Other Health-Related Nutraceutical, Skincare and Pet Pro
NutraLife Biosciences Inc. Engages CFN Media to Reach, Attract Retail, Accredited & Institutional Investors
NUTRALIFE BIOSCIENCES, INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
NutraLife BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
NUTRALIFE BIOSCIENCES, INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
NutraLife BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. NLBS Aktie
  4. Nachrichten NutraLife BioSciences, Inc.
  5. Andere Sprachen